PRKDC

Across TCGA pan-cancer cohorts, PRKDC Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated PRKDC data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PRKDC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRKDC expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

THYM, BLCA, and MESO are the cancer types where PRKDC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BLCA	OS	Median	III,IV	0.871	0.339	.001	27	view →
MESO	OS	Median	II,III,IV	0.121	0.571	.004	18	view →
SARC	DFS	Median	All	0.108	0.617	<.001	18	view →
ESCA	DFS	Median	III,IV	0.181	0.458	.008	18	view →
COAD	OS	Median	III,IV	0.209	0.806	<.001	17	view →
READ	OS	Median	III,IV	0.289	0.932	<.001	15	view →
THCA	DFS	Median	All	0.161	0.829	.007	9	view →
UCEC	DFS	Median	All	0.800	0.610	.017	6	view →
GBM	OS	Median	All	0.109	0.415	.032	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PRKDC–THYM (OS)

Open the THYM breakdown →